Vice President, Operations
CurrentAllterum Therapeutics, Inc. is a Fannin-founded biopharmaceutical company targeting CD127 (IL-7Ra)-expressing cancers with an initial focus on patients with Acute Lymphoblastic Leukemia (ALL). The company's lead candidate, 4A10, is a monoclonal antibody targeting CD127 in-licensed from NCI which is expected to enter clinic in 1H 2025. I have a range of responsibilities including manufacturing process oversight, financial projections, intellectual property, licensing, agreements, grant applications, and grant management.